No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer

A 5-year follow-up study

Li Ting Kao, Herng Ching Lin, Shiu Dong Chung, Chao Yuan Huang

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Prior studies suggested that the use of androgen deprivation therapy (ADT) in patients with prostate cancer (PC) might cause the impairment of cognitive function which is one of the common symptoms of dementia; however, the association between ADT and cognitive impairment still remains controversial. This retrospective cohort study aimed to investigate the relationship between ADT and subsequent risk of dementia using a population-based dataset. Data for this study were taken from the Taiwan (China) Longitudinal Health Insurance Database 2005. We included 755 PC patients who received ADT in the study cohort and 559 PC patients who did not receive ADT in the comparison cohort. Each patient was individually tracked for a 5-year period to define those who subsequently received a diagnosis of dementia. Results show that the incidence rates of dementia per 100 person-years were 2.35 (95% confidence interval [95% CI]: 1.82-2.98) and 1.85 (95% CI: 1.35-2.48) for PC patients who received ADT and those who did not receive ADT, respectively. The adjusted hazard ratio (HR) for dementia for PC patients who received ADT was 1.21 (95% CI: 0.82-1.78, P = 0.333) compared to those who did not receive ADT. In addition, the adjusted HRs for dementia for PC patients receiving ADT with gonadotropin-releasing hormone (GnRH) agonists and without GnRH agonists were 1.39 (95% CI: 0.80-2.40, P = 0.240) and 1.13 (95% CI: 0.75-1.71, P = 0.564), respectively, compared to PC patients not receiving ADT. We concluded that there was no difference in the risk of subsequent dementia between PC patients who did and those who did not receive ADT.

Original languageEnglish
JournalAsian Journal of Andrology
Volume18
DOIs
Publication statusPublished - 2017

Fingerprint

Androgens
Dementia
Prostatic Neoplasms
Confidence Intervals
Therapeutics
Gonadotropin-Releasing Hormone
Cohort Studies
Health Insurance
Taiwan
Cognition
China
Retrospective Studies
Databases
Incidence

Keywords

  • Androgen deprivation therapy
  • Dementia
  • Epidemiology
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer : A 5-year follow-up study. / Kao, Li Ting; Lin, Herng Ching; Chung, Shiu Dong; Huang, Chao Yuan.

In: Asian Journal of Andrology, Vol. 18, 2017.

Research output: Contribution to journalArticle

@article{b44b3b74682444a38f57800bf254a9cd,
title = "No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer: A 5-year follow-up study",
abstract = "Prior studies suggested that the use of androgen deprivation therapy (ADT) in patients with prostate cancer (PC) might cause the impairment of cognitive function which is one of the common symptoms of dementia; however, the association between ADT and cognitive impairment still remains controversial. This retrospective cohort study aimed to investigate the relationship between ADT and subsequent risk of dementia using a population-based dataset. Data for this study were taken from the Taiwan (China) Longitudinal Health Insurance Database 2005. We included 755 PC patients who received ADT in the study cohort and 559 PC patients who did not receive ADT in the comparison cohort. Each patient was individually tracked for a 5-year period to define those who subsequently received a diagnosis of dementia. Results show that the incidence rates of dementia per 100 person-years were 2.35 (95{\%} confidence interval [95{\%} CI]: 1.82-2.98) and 1.85 (95{\%} CI: 1.35-2.48) for PC patients who received ADT and those who did not receive ADT, respectively. The adjusted hazard ratio (HR) for dementia for PC patients who received ADT was 1.21 (95{\%} CI: 0.82-1.78, P = 0.333) compared to those who did not receive ADT. In addition, the adjusted HRs for dementia for PC patients receiving ADT with gonadotropin-releasing hormone (GnRH) agonists and without GnRH agonists were 1.39 (95{\%} CI: 0.80-2.40, P = 0.240) and 1.13 (95{\%} CI: 0.75-1.71, P = 0.564), respectively, compared to PC patients not receiving ADT. We concluded that there was no difference in the risk of subsequent dementia between PC patients who did and those who did not receive ADT.",
keywords = "Androgen deprivation therapy, Dementia, Epidemiology, Prostate cancer",
author = "Kao, {Li Ting} and Lin, {Herng Ching} and Chung, {Shiu Dong} and Huang, {Chao Yuan}",
year = "2017",
doi = "10.4103/1008-682X.179528",
language = "English",
volume = "18",
journal = "Asian Journal of Andrology",
issn = "1008-682X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer

T2 - A 5-year follow-up study

AU - Kao, Li Ting

AU - Lin, Herng Ching

AU - Chung, Shiu Dong

AU - Huang, Chao Yuan

PY - 2017

Y1 - 2017

N2 - Prior studies suggested that the use of androgen deprivation therapy (ADT) in patients with prostate cancer (PC) might cause the impairment of cognitive function which is one of the common symptoms of dementia; however, the association between ADT and cognitive impairment still remains controversial. This retrospective cohort study aimed to investigate the relationship between ADT and subsequent risk of dementia using a population-based dataset. Data for this study were taken from the Taiwan (China) Longitudinal Health Insurance Database 2005. We included 755 PC patients who received ADT in the study cohort and 559 PC patients who did not receive ADT in the comparison cohort. Each patient was individually tracked for a 5-year period to define those who subsequently received a diagnosis of dementia. Results show that the incidence rates of dementia per 100 person-years were 2.35 (95% confidence interval [95% CI]: 1.82-2.98) and 1.85 (95% CI: 1.35-2.48) for PC patients who received ADT and those who did not receive ADT, respectively. The adjusted hazard ratio (HR) for dementia for PC patients who received ADT was 1.21 (95% CI: 0.82-1.78, P = 0.333) compared to those who did not receive ADT. In addition, the adjusted HRs for dementia for PC patients receiving ADT with gonadotropin-releasing hormone (GnRH) agonists and without GnRH agonists were 1.39 (95% CI: 0.80-2.40, P = 0.240) and 1.13 (95% CI: 0.75-1.71, P = 0.564), respectively, compared to PC patients not receiving ADT. We concluded that there was no difference in the risk of subsequent dementia between PC patients who did and those who did not receive ADT.

AB - Prior studies suggested that the use of androgen deprivation therapy (ADT) in patients with prostate cancer (PC) might cause the impairment of cognitive function which is one of the common symptoms of dementia; however, the association between ADT and cognitive impairment still remains controversial. This retrospective cohort study aimed to investigate the relationship between ADT and subsequent risk of dementia using a population-based dataset. Data for this study were taken from the Taiwan (China) Longitudinal Health Insurance Database 2005. We included 755 PC patients who received ADT in the study cohort and 559 PC patients who did not receive ADT in the comparison cohort. Each patient was individually tracked for a 5-year period to define those who subsequently received a diagnosis of dementia. Results show that the incidence rates of dementia per 100 person-years were 2.35 (95% confidence interval [95% CI]: 1.82-2.98) and 1.85 (95% CI: 1.35-2.48) for PC patients who received ADT and those who did not receive ADT, respectively. The adjusted hazard ratio (HR) for dementia for PC patients who received ADT was 1.21 (95% CI: 0.82-1.78, P = 0.333) compared to those who did not receive ADT. In addition, the adjusted HRs for dementia for PC patients receiving ADT with gonadotropin-releasing hormone (GnRH) agonists and without GnRH agonists were 1.39 (95% CI: 0.80-2.40, P = 0.240) and 1.13 (95% CI: 0.75-1.71, P = 0.564), respectively, compared to PC patients not receiving ADT. We concluded that there was no difference in the risk of subsequent dementia between PC patients who did and those who did not receive ADT.

KW - Androgen deprivation therapy

KW - Dementia

KW - Epidemiology

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85051891585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051891585&partnerID=8YFLogxK

U2 - 10.4103/1008-682X.179528

DO - 10.4103/1008-682X.179528

M3 - Article

VL - 18

JO - Asian Journal of Andrology

JF - Asian Journal of Andrology

SN - 1008-682X

ER -